[A22-95] Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V

Last updated 01.12.2022

Project no.:

Commission awarded on 31.08.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Head and nerves


Adult patients who have at least 4 migraine days per month

Result of dossier assessment:
  • Untreated and pretreated patients for whom conventional migraine prophylaxis is an option: added benefit not proven
  • Patients who do not respond to any of the following drug treatments/drug classes, for whom they are unsuitable, or who do not tolerate them: metoprolol, propranolol, flunarizine, topiramate, amitriptyline, clostridium botulinum toxin type A: added benefit not proven

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form